In this patient who developed resistance to crizotinib after 5 months of treatment, molecular analyses showed the tumor had two acquired mutations within the kinase domain of EML4-ALK, C1156Y, and the gatekeeper mutation L1196M (Katayama et al., 2011). The gene discussed is EML4; the disease is neoplasm.